PIPELINE

Envafolimab (KN035), TRACON has rights to develop and commercialize envafolimab in sarcoma in North America.

1

INDICATION
Undifferentiated Pleomorphic Sarcoma (UPS)/Myxofibrosarcoma (MFS) in the U.S.

ENVASARC PHASE 2 (PIVOTAL)

Solid Tumors (in U.S.)

PHASE 1

Solid Tumors (in Japan)

PHASE 1

Solid Tumors (in China)

PHASE 1

Gastric Cancer (in China)

PHASE 2

MSI-H Advanced Solid Tumors (in China)

PHASE 2 (PIVOTAL)

Biliary Tract Cancer (in China)

PHASE 3 (PIVOTAL)

YH001

Solid Tumors
2

PHASE 1 Single Agent
PHASE 1 with Toripalimab

TRC102

INDICATION

Mesothelioma

PHASE 2

Lung, Solid Tumors

PHASE 1

TJ4309

INDICATION

Tumors
3

PHASE 1

Bispecific Antibodies

INDICATION

Tumors
3

PRE-CLINICAL

1 Strategic partnership with 3D Medicines and Alphamab Oncology
2 Strategic partnership with Eucure Biopharma
3 Strategic partnership with I-Mab Biopharma